PRVA

EX-99.1

2 ex-9911q26earningrelease.htm

EX-99.1

Document

Exhibit 99.1

Privia Health Reports First Quarter 2026 Financial Results

–Strong First Quarter Performance and Operating Execution

–Reiterated Full-Year 2026 Guidance Reflects Continued Momentum

ARLINGTON, VA – May 7, 2026 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the first quarter ended March 31, 2026.

Three Months Ended March 31,

(unaudited; $ in millions, except per share amounts) 20262025 Change (%)*

Total revenue$603.8 $480.1 25.8 %

Gross profit $125.6 $103.6 21.2 %

Operating income$7.4 $5.2 42.2 %

Net income a $3.1 $4.2 (27.4)%

Non-GAAP adjusted net income b

$24.3 $19.9 22.3 %

Net income per share$0.02 $0.03 (33.3)%

Non-GAAP adjusted net income per share b

$0.19 $0.16 18.8 %

*Any slight variations in totals are due to rounding.

a.Net income for the three months ended March 31, 2026, included $21.9 million in non-cash stock compensation expense. Net income for the three months ended March 31, 2025 included $17.8 million in non-cash stock compensation expense.

b.Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release.

First Quarter 2026 highlights include:

•Continued strength in same-store growth and new provider additions;

•Practice Collections of $914.8M, +14.6% versus 1Q’25; and

•Adjusted EBITDA c e f of $36.7M, +36.3% versus 1Q’25.

Key Operating and Non-GAAP Financial Metrics c

Three Months Ended March 31,

(unaudited; $ in millions) 20262025Change (%)

Implemented Providers5,535 4,871 13.6 %

Value-Based Care Attributed Lives1,606,000 1,270,000 26.5 %

Practice Collections$914.8 $798.6 14.6 %

Care Margin $128.7 $105.3 22.3 %

Platform Contribution $67.0 $51.7 29.6 %

Adjusted EBITDA $36.7 $26.9 36.3 %

c.Reconciliations of Care Margin, Platform Contribution, Adjusted EBITDA and other non-GAAP financial measures are presented in tables near the end of this press release.

1

Updated Full-Year 2026 Guidance d e f g

Privia Health maintained its full-year 2026 outlook for most metrics, and raised its guidance range for Attributed Lives, as follows:

FY 2025

Initial FY 2026 Guidance at 2.27.26 d

Updated FY 2026 Guidance at 5.7.26

($ in millions)ActualLowHigh

Implemented Providers5,380 5,9006,000Unchanged

Attributed Lives1,541,000 1,550,0001,600,0001,600,000 - 1,625,000

Practice Collections$3,470.5 $3,650 $3,750 Unchanged

GAAP Revenue$2,122.8 $2,350 $2,450 Unchanged

Care Margin d e f $462.2 $515 $530 Unchanged

Platform Contribution d e $234.8 $260 $270 Unchanged

Adjusted EBITDA d e f $125.5 $145 $155 Unchanged

•Expect approximately 80% of Adjusted EBITDA to convert to free cash flow in full-year 2026

•Guidance does not assume any new business development activity

d.Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of Gross Profit, Operating Income and Net Income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.

e.See “Key Metrics and Non-GAAP Financial Measures” for more information as to how the Company defines and calculates Implemented Providers, Attributed Lives, Practice Collections, Care Margin, Platform Contribution, and Adjusted EBITDA, and for a reconciliation of the most comparable GAAP measures to Care Margin, Platform Contribution, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income Per Share.

f.Certain non-recurring or non-cash and other expenses will be treated as an add back in the reconciliation of Net Income to Adjusted EBITDA, and the reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share, the details of which can be found in the Reconciliation schedules near the end of this and in future quarterly press releases.

g.Any slight variations in totals due to rounding.

Webcast and Conference Call Information

The Company will host a conference call on May 7, 2026, at 8:00 am ET to discuss these results and management’s outlook for future financial and operational performance. You can visit ir.priviahealth.com/news-and-events/events-and-presentations to listen to the call via live webcast. The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call under the same link. If you wish to participate in the live conference call, then please dial 888-596-4144 (or 646-968-2525 for international callers) and provide Conference ID 5704885.

This news r

prva-202602260001759655FALSE00017596552026-02-262026-02-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2026

Privia Health Group, Inc. (Exact Name of Registrant as Specified in Its Charter)

Delaware 001-4036581-3599420 (State or other jurisdiction of incorporation or organization) (Commission File No.)(I.R.S. Employer Identification No.)

950 N. Glebe Rd., Suite 700 Arlington,Virginia22203 (Address of Principal Executive Offices) (Zip Code)

(571) 366-8850 Registrant's telephone number, including area code

Not Applicable (Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 par value per sharePRVAThe Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 26, 2026, Privia Health Group, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit:

Exhibit No.Description 99.1Privia Health Group, Inc. Press Release Dated February 26, 2026

104The Cover Page from this Current Report on Form 8-K, Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRIVIA HEALTH GROUP, INC.

Date: February 26, 2026 By:/s/ David Mountcastle

Name: David Mountcastle Title: Executive Vice President, Chief Financial Officer and Authorized Officer

prva-202511060001759655FALSE00017596552025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Privia Health Group, Inc. (Exact Name of Registrant as Specified in Its Charter)

Delaware 001-4036581-3599420 (State or other jurisdiction of incorporation or organization) (Commission File No.)(I.R.S. Employer Identification No.)

950 N. Glebe Rd., Suite 700 Arlington,Virginia22203 (Address of Principal Executive Offices) (Zip Code)

(571) 366-8850 Registrant's telephone number, including area code

Not Applicable (Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 par value per sharePRVAThe Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Privia Health Group, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit:

Exhibit No.Description 99.1Privia Health Group, Inc. Press Release Dated November 6, 2025

104The Cover Page from this Current Report on Form 8-K, Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRIVIA HEALTH GROUP, INC.

Date: November 06, 2025 By:/s/ David Mountcastle

Name: David Mountcastle Title: Executive Vice President, Chief Financial Officer and Authorized Officer